Obesity
🇺🇸 FDA Page 2FDA news and analysis for pharmaceutical BD, investment, and market access · 12 articles on this page
Gain critical insights into global obesity drug development, market trends, and regulatory landscapes. Drive your pharma strategy with NovaPharmaNews intelligence.
Showing 13–24 of 34 articles
Pfizer's Berobenatide: Monthly Obesity Drug Shows Promise in Phase 2b
STAT+: Newer GLP-1s, pushback on research cuts, and a protest
MIRA Pharma Consolidates Global Rights to MIRA-55 and SKNY-1
Tip Sheet GLP-1s and Cancer: Key Insights for Pharma BD and Investors
Design Therapeutics' Friedreich's Ataxia Data and Vincentage's Obesity Results: A Strategic Analysis
Spotlight On: Four Things to Watch at ADA 2026
Medicare's GLP-1 Stance and UnitedHealthcare Lawsuit: Key Implications for Pharma
Hepatitis B Drug Developments and Lilly's Obesity Drug Returns
Kailera’s Three-Pronged Obesity Shot Shows Promise in Early Trial
Lilly's Triple-Acting Obesity Drug Achieves Phase 3 Trial Goals
Lilly's Triple Agonist: Leading the Charge in Obesity Treatment
ASCO 2026 Oncology Drug Pipeline Preview